NeonMind Developing Music Playlist For Psychedelic Therapy Sessions


Ryan Allway

April 6th, 2021

Psychedelics


Vancouver, B.C. – April 6, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (OTC:NMDBF) (“NeonMind”), is pleased to announce the commencement of a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions.  Previous research has established that music for a therapeutic psychedelic session can significantly impact the experience.

 

“The emotional arc of a musical playlist during a psychedelic session can play an important role in supporting someone’s therapeutic experience,” says Rob Tessarolo, President & CEO of NeonMind. “Music can act as a pathway that is followed throughout the patient’s journey, taking them to places on an emotional level that they wouldn’t necessarily go without it. Working with Dr. Russo and his team means we’re able to scientifically investigate what have to date been assumptions about what makes a good playlist.”

 

NeonMind is working with  Dr. Frank Russo, a professor of Psychology at Ryerson University, who conducts research on the biological, cognitive, and social-emotional bases of music and speech at the Science of Music Auditory Research and Technology (SMART) Lab.  He is also an affiliate scientist at the Toronto Rehabilitation Institute, a core member of the McMaster Institute for Music and the Mind, and an adjunct professor at the University of Toronto’s Music and Health Collaboratory.

 

NeonMind will conduct the research in  three phases:

  • an online playlist candidate validation study, surveying 50 people with relation to the self-transcendent emotions experienced when listening to snippets of longer musical tracks;
  • an in-person playlist validation study at Ryerson’s SMART Lab; and
  • a comprehensive in-person physiological validation study measuring biological markers to further substantiate the potential for self-transcendent emotions that the playlist in question generates.

 

“This is an exciting frontier to be a part of that dovetails nicely with several aspects of research that I’ve been conducting into the psychology of music throughout my career,” says Dr. Russo. “Music without a psychedelic has the potential to generate self-transcendent emotions such as compassion and awe, which may be transformative; on the basis of past research on music and psychedelics, it seems that the music a person listens to during a therapeutic trip is a major determinant of the overall experience. The playlist we are working towards takes various theoretical considerations into account, and the series of studies we’ve designed will enable us to iteratively assess and refine its efficacy.”

 

Each phase will help the team assess and fine-tune the playlist which will then be used in NeonMind’s clinical trials and for the enhancement of psychedelic-assisted psychotherapy services.

 

 

About NeonMind Biosciences Inc.

NeonMind is engaged in research and development of products to optimize human health and performance. NeonMind has two divisions, a pharmaceutical division engaged in drug development of psychedelic compounds, and a consumer products division with a focus on mushroom infused products. NeonMind’s consumer division currently sells medicinal mushroom infused coffee products in Canada through NeonMind’s direct to consumer e-commerce platform. It also plans to launch medicinal dietary supplements in the U.S. this spring.

 

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s first drug candidate aims to use synthetic psilocybin to enhance a patient’s ability to adopt behaviours that cause weight loss and maintain that loss  through psychedelic-assisted cognitive therapy.  The second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.

 

NeonMind’s first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is involved in the hallucinogenic effect of psychedelics, and the second drug candidate employs low-dose psilocybin as an agonist to the 5-HT2C receptor, which controls appetite.

 

For more information on NeonMind, go to www.NeonMindBiosciences.com or buy NeonMind mushroom infused coffee at www.NeonMind.com.

 

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

[email protected]

Tel: 416-750-3101

 

 

Investor Relations:

Edge Communications

[email protected]

Tel: 1-866-318-6874

 

 

Renmark Financial Communications Inc.

Melanie Barbeau

[email protected]

Tel: 416-644-2020 or 212-812-7680

 

 

Media Inquiries:

Exvera Communications Inc.

[email protected]

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”,”estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading